Drug Trial Radar · NCT00425555
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Jan 2007
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Conditions
- Cutaneous T-Cell Lymphoma
Interventions
PanobinostatDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT)Time frame: Baseline up to 6 Months of Follow up
Locations
42 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham/ Kirklin Clinic Kirklin Clinic
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
University of California at Los Angeles Dept. of Hematology-Oncology
Los Angeles, California
Florida Academic Dermatology Center
Miami, Florida
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
Atlanta, Georgia
Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia
Augusta, Georgia
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed
Chicago, Illinois
Indiana University Dept. of IU Cancer Center
Indianapolis, Indiana
Boston Medical Center StudyCoordinator:CLBH589B2201
Boston, Massachusetts
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3)
Boston, Massachusetts
University of Michigan Health System Michigan HouseClinTrialsOffice
Ann Arbor, Michigan
Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr
Winston-Salem, North Carolina
University Dermatology Consultants
Cincinnati, Ohio
Oregon Health & Science University Dept. of OHSU Cancer Institute
Portland, Oregon
University of Pittsburgh Medical Center Department of Dermatology
Pittsburgh, Pennsylvania
MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201
Houston, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
South Brisbane, Queensland, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Yvoir, Belgium
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Lyon, Cedex 02, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Minden, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.